Senetek
This article was originally published in The Rose Sheet
Executive Summary
Skin care ingredient supplier inks licensing deal with Age Advantage Labs to develop Age Eraser crème containing Senetek's patented Kinetin anti-aging compound, firms announce. Product will be marketed to spa, department store and health store doors. "This license takes us another step closer to achieving Senetek's goal of making Kinetin-based skin care available to consumers across the full spectrum of retail channels of distribution," company notes. Other Kinetin licensees include Revlon and The Body Shop. Senetek also markets the Kinetin Plus brand, introduced earlier this year (1"The Rose Sheet" May 26, 2003, In Brief)...
You may also be interested in...
Kinetin sales
Senetek proprietary skin care line, Kinetin Plus, will lessen dependence on licensees and capitalize on intellectual property, CEO Frank Massino says. Product line will include eight SKUs to be test marketed in spas and salons and online, exec adds during firm's May 15 first quarter sales and earnings announcement. Senetek is developing science-based educational infomercial for testing in August. Senetek sales declined 17% in Q1 to $2.1 mil., due to a reduction in product sales and royalties, company says. Royalty declines stemmed from 33% reduction in royalties from Revlon, which experienced lower than anticipated unit sales of its Almay Kinetin brand. Senetek recorded net loss of $69,000 for the three months, compared to income of $504,000 a year ago...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.